+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 75Years
All Genders
ID07068165

Comparing Lenalidomide and Prednisone Treatments for Active Proliferative IgG4-Related Disease in Adults Aged 18 to 75

Led by Peking Union Medical College Hospital · Updated on 2025-12-30

198

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of lenalidomide combined with prednisone compared to prednisone alone in adults with active proliferative IgG4-related disease IgG4-RD. This trial aims to find new treatment options for this condition by conducting a 52-week randomized controlled study. Patients meeting specific IgG4-RD activity criteria are included to assess how well these treatments work and their safety. Participants are assigned to one of three groups 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, or prednisone alone. Prednisone is given initially at 0.6-0.8 mgkgday for 2-4 weeks, then gradually reduced every 1-2 weeks until stopped within 24 weeks. The treatments continue with monitoring through the 52-week study period. During the study, participants will have regular assessments at 4, 12, 24, 36, and 52 weeks to measure disease activity, treatment response, serum IgG4 levels, and safety. Researchers will track recurrence rates and changes in disease indices, along with the physicians overall evaluation. The total participation time is 52 weeks, with close monitoring for treatment effects and safety throughout the trial.

CONDITIONS

Brief Title

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here